LXRX LEXICON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1062822 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY9.1%
TTM EPS YoY21.1%
Revenue 3-yr CAGR317.1%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-147.4%
Net margin-161.8%
FCF margin—
EBITDA margin-146.3%
Returns
ROE-43.9%
ROA-27.8%
ROIC (approx.)-33.3%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets32.3%
Debt / equity0.32x
Current ratio10.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $49.80M | $31.08M |
| Cost of revenue | $274,000 | $616,000 |
| Gross profit | $49.53M | $30.46M |
| R&D expense | $61.12M | $84.48M |
| SG&A expense | $37.32M | $143.10M |
| Operating income | -$48.91M | -$197.12M |
| Income tax | — | $0 |
| Net income | -$50.34M | -$200.40M |
| EBITDA | -$48.29M | -$196.58M |
| EPS (basic) | -0.14 | -0.63 |
| EPS (diluted) | -0.14 | -0.63 |
| Weighted avg. shares (diluted) | 363.05M | 320.03M |
| Balance sheet | ||
| Cash & equivalents | $34.33M | $66.66M |
| Short-term investments | $61.90M | $171.30M |
| Receivables | $2.38M | $3.47M |
| Inventory | $281,000 | $231,000 |
| Current assets | $101.89M | $246.19M |
| PP&E, net | $1.86M | $2.48M |
| Goodwill | $44.54M | $44.54M |
| Total assets | $184.99M | $298.42M |
| Current liabilities | $20.87M | $45.25M |
| Short-term debt | $4.59M | $0 |
| Long-term debt | $49.41M | $100.30M |
| Total debt | $54.00M | $100.30M |
| Total liabilities | $77.45M | $152.47M |
| Shareholders' equity | $107.54M | $145.95M |
| Net debt | $19.68M | $33.64M |
| Shares outstanding | 365.85M | 363.02M |
| Cash flow statement | ||
| Operating cash flow | -$67.85M | -$178.78M |
| Capital expenditure | $0 | $1.03M |
| Free cash flow | -$67.85M | -$179.81M |
| Investing cash flow | $113.02M | -$15.38M |
| Financing cash flow | -$48.50M | $238.35M |
| Depreciation & amortization | $621,000 | $534,000 |
| Stock-based compensation | $12.52M | $13.50M |
| Share buybacks | — | $1.73M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.